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Background: Until now, herpes zoster (HZ)-related disease burden in Germany has been estimated based on health
insurance data and clinical findings. However, the validity of self-reported HZ is unclear. This study investigated the
validity of self-reported herpes zoster (HZ) and its complication postherpetic neuralgia (PHN) using data from the
pretest studies of the German National Cohort (GNC) in comparison with estimates based on health insurance data.
Methods: Data of 4751 participants aged between 20 and 69 years from two pretest studies of the GNC carried out in
2011 and 2012 were used. Based on self-reports of physician-diagnosed HZ and PHN, age- and sex-specific HZ incidence
rates and PHN proportions were estimated. For comparison, estimates based on statutory health insurance data from the
German population were considered.
Results: Eleven percent (95%-CI, 10.4 to 12.3, n= 539) of the participants reported at least one HZ episode in their
lifetime. Our estimated age-specific HZ incidence rates were lower than previous estimates based on statutory health
insurance data. The PHN proportion in participants older than 50 years was 5.9% (1.9 to 13.9%), which was in line with
estimates based on health insurance data.
Conclusion: As age- and sex-specific patterns were comparable with that in health insurance data, self-reported
diagnosis of HZ seems to be a valid instrument for overall disease trends. Possible reasons for observed differences in
incidence rates are recall bias in self-reported data or overestimation in health insurance data.
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Herpes zoster (HZ, also known as shingles) is a painful skin
rash with blisters in a localized area, which is caused by the
reactivation of a latent varicella zoster virus (VZV) infec-
tion [1]. Since HZ mostly affects elderly individuals, the
number of HZ cases will increase in the next decades due
to demographic changes in developed countries [2], which
are characterized by decreasing fertility rates and increasing
life expectancy leading to considerable changes in the age
structure of societies. About 5 to 30% of subjects with HZ
experience postherpetic neuralgia (PHN) [3]; the latter is
often accompanied by a substantial impairment of quality
of life and is associated with considerable health care costs
[2]. In large-scale prospective cohort studies (such as the
German National Cohort (GNC)), history of HZ is assessed
based on face-to-face interviews or patient-administered
questionnaires. The validity of self-reported HZ diagnoses
obtained in this way is, however, unclear. Previous studies
demonstrated that diseases causing severe long-term re-
striction of quality of life, which is associated with intensive
medical therapies and frequent visits to the physician, are
remembered well. This applies to chronic or long-term dis-
eases such as cancer, diabetes, and rheumatoid arthritis,
which have been shown to be reported with reasonable
accuracy [4–8]. Similar results were also shown for
event-type diseases with a strong emotional component
and long-term consequences such as stroke or myocardial
infarction [8–13]. In contrast, HZ without PHN has no
long-term consequences, and even the treatment of a PHN
episode is predominantly temporarily limited [14]. Based
on these considerations, findings on validity of reporting
for other diseases might not be applicable to HZ, making a
separate assessment necessary. Typically, the validity of
self-reported diagnoses is assessed by directly comparing
diagnoses on individual level with a gold standard (such as,
medical records [7, 15], inquiry of the primary physician
[16, 17], or a physical examination [4, 18]). An alternative
method of indirect validation is the comparison of aggre-
gated disease frequency measures with other studies or data
sources [19], particularly if they are collected at population
level. We have realized this approach by using the compre-
hensive data set of the pretest studies of the GNC. The aim
was to assess the validity of self-reported diagnoses of HZ
by comparing our estimates at population level with those
derived from studies based on statutory health insurance
data in Germany.
Methods
Data source
The GNC is a nationwide prospective population-
based cohort study with an anticipated number of
200,000 participants recruited in 18 study centers in
Germany; the baseline assessment started in 2014
[20]. For planning and preparing of the GNC, twocross-sectional feasibility studies (pretests 1 and 2)
were carried out in 2011 and 2012, respectively. The
participants were recruited via age-stratified random
sampling from regional population registration offices.
The recruitment strategy characteristics varied be-
tween study centers, but procedures were similar
across study centers [21]. The response proportions
ranged from 10 to 51% depending on study center
[21, 22]. In order to obtain the necessary number of
study participants in certain age strata, additionally a
small proportion of convenience participants (less
than 10%) were enrolled in some study centers. Study
participants performed computer-assisted face-to-face
interviews to assess their medical history, socio-
demographic and economic characteristics, and they
underwent various medical examinations; moreover,
biological samples such as blood, urine, stool, nasal
and pharyngeal swabs were collected.
In the current analysis 2647 participants of pretest 1
and 2897 participants of pretest 2 were included. For the
assessment of HZ disease status, the following questions
from the core interview were used:
Question 1: “Have you ever been diagnosed with
shingles (herpes zoster) by a physician?”
Question 2: “Have you been diagnosed with shingles
(herpes zoster) by a physician in the last twelve
months?”
And if question 1 was answered with yes:
Question 3: “At what age (in which year) have you
been diagnosed with shingles (herpes zoster)?”
Question 4: “Have you ever been diagnosed by a
physician with postherpetic neuralgia as a
complication of shingles (herpes zoster)?”
PHN (as assessed by question 4) was considered
only in pretest 2 and was defined as “…severe pain in
the area of shingles-rash, lasting longer than 4
months”. Only participants answering question 1 with
“Yes” could specify if they had ever been diagnosed
with PHN. The answer options to questions 1, 2, and
4 were “Yes”, “No”, and “Don’t know”. Regarding ques-
tion 3, the participants could either report the year of
diagnosis or the age at the time of diagnosis of HZ.
Pretest study participants were included in this
analysis if information on age, sex, and at least one
question regarding their HZ disease history was avail-
able. Participants outside the intended age-range for
the GNC (20 to 69 years) were excluded from the
current analysis.
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different studies were used for comparison, described in
detail in Table 1 [2, 23, 24].Statistical analysis
After excluding individuals with missing data on his-
tory of HZ, age or sex we performed a complete case
analysis. Firstly, using the pretest data, we directly es-
timated the crude annual HZ incidence rate (IR)
based on the presence of HZ in the past 12 months
(question 2). Secondly, using reported diagnosed HZ
cases (question 1) and the age at diagnosis (question
3), we calculated the cumulative incidence of HZ, tak-
ing into account all HZ cases reported up to a given
age, divided by the number of individuals of that age
or older. In case of missing information regarding age
at HZ diagnosis, we performed an imputation. We
used proportions according to the distribution of age
at HZ diagnosis among individuals up to 5 years
older/younger than the individual with missing infor-
mation as weights. We further assessed whether there
was a difference in the reported cumulative incidence
of HZ for four different birth cohorts. For this pur-
pose, we subdivided the study population into cohorts
born in 10-year intervals. To investigate whether sex
differently affects the hazard of HZ in the 10-year
cohort, we used Cox regression. Thirdly, based on the
data collected in questions 1 and 3, we estimated IR
of HZ in 10-year age-groups by dividing cases occur-
ring in the respective age-bands by the corresponding
person-time (censored at age of HZ or age at inter-
view for those not reporting HZ). Subsequently, we
compared IR calculated by this approach with IR
from three studies using health insurance data from
the German population [2, 23, 24]. Fourthly, we
assessed the proportion of participants with HZ who
experienced PHN and compared it with estimates
based on health insurance data [2]. Study participants
answering “Don’t know” on the question of whether
they had HZ were excluded from the main analysis.
The statistical analyses were performed using SAS
version 9.3 (Basic, SAS Institute Inc., Cary, North
Carolina, USA) and R (version 3.2.4).Table 1 Studies using statutory health insurance data of the Germa
First author (year) Data collection year Data
Ultsch (2013) [2] 2004 to 2009 SHI A
Ultsch (2011) [23] 2007 to 2008 ASHIP
Hillebrand (2014) [24] 2005 to 2009 GePaR
AOK “Allgemeine Ortskrankenkasse”, ASHIP Association of Statutory Health Insuranc
confidence interval, HZ herpes zoster, KV Regional Association of SHI-Accredited Ph
aASHIP organized in 17 units largely consistent with 16 federal states of Germany; in
bOnly subjects over 50 years of age included
cData from three SHIsResults
Baseline characteristics of the study population
After assessment of inclusion and exclusion criteria,
4751 (85.7%) of the 5544 pretest participants were in-
cluded in the analysis (Fig. 1). The most frequent rea-
son for exclusion was missing information on HZ
status (n = 691), since some study centers did not im-
plement the questions on HZ disease history for parts
of or even for the entire pretest study period. In
addition, 59 participants did not meet the predefined
GNC age-range of 20 to 69 years. Also, 27 participants
who stated that they did not know whether they had ever
experienced HZ were excluded from the current analysis.
The proportion of female participants was slightly higher
in both pretest studies (54.9%) than in the German popu-
lation of this age-range (50.0%) (Table 2). Most of the par-
ticipants were in the age-group 60 to 69 years (32.7% of all
participants). The majority of participants had a higher
education entrance qualification (46.5%). Eleven percent
(n = 539) of participants reported having ever been diag-
nosed with HZ.Crude annual herpes zoster incidence rate
Twenty-nine participants reported a HZ episode in the
past 12 months, resulting in a crude IR of 6.2 per 1000 PY
(95%-CI: 3.9 to 8.4) for both pretest studies combined.Cumulative incidence of herpes zoster
The cumulative incidence of HZ was similar in males
and females up to the age of 40 years (Fig. 2, left panel).
Above the age of 40 years, the cumulative incidence in-
crease with age was more pronounced among female
than male participants, resulting in a cumulative inci-
dence of 22.6% (95%-CI: 19.8 to 25.9%) in females and
15.9% (95%-CI: 13.3 to 18.9%) in males at 69 years of
age. This observation was confirmed by the results of
the Cox regression analysis (Table 3); up to the age of
40 years, no sex-specific effects on HZ incidence were
observed. Above the age of 40 years, female participants
had about two times higher hazard of HZ than male
participants.
The cumulative incidence was higher in the younger
birth cohorts (1984 to 1993, 1974 to 1983 and 1964 ton population for estimating HZ incidence rates
source HZ incidence rate per 1000 PY (95%-CI)
OK Hesse/KV Hesse 5.8 (5.6 to 5.9)
databasea 9.6 (9.6 to 9.6)b
Dc 6.0 (5.9 to 6.0)
e Physicians, GePaRD German Pharmacoepidemiological Research Database, CI
ysicians, SHI statutory health insurance
2007 data on 14 ASHPIs and in 2008 data on 11 ASHIPs
Fig. 1 Flow chart of the study population
Table 2 Baseline characteristics of included study participants of pretest 1 and 2 of the GNC
Variables Male (n = 2145)
n (%)
Female (n = 2606)
n (%)
Total (n = 4751)
n (%)
Age-group in years
20 to 29 170 (7.9) 233 (8.9) 403 (8.5)
30 to 39 212 (9.9) 249 (9.6) 461 (9.7)
40 to 49 481 (22.4) 601 (23.1) 1082 (22.8)
50 to 59 542 (25.3) 709 (27.2) 1251 (26.3)
60 to 69 740 (34.5) 814 (31.2) 1554 (32.7)
Median age in years (IQR) 53 (44 to 62) 52 (43 to 61) 53 (43 to 62)
Education levela
High 1067 (49.7) 1143 (43.9) 2210 (46.5)
Intermediate 300 (14.0) 596 (22.9) 896 (18.9)
Low 717 (33.4) 785 (30.1) 1502 (31.6)
Without school-leaving certificate 29 (1.4) 35 (1.3) 64 (1.3)
Missing data 32 (1.5) 47 (1.8) 79 (1.7)
Herpes zoster cases 209 (9.7) 330 (12.7) 539 (11.3)
IQR interquartile range
aLow: without school-leaving certificate or lower secondary school certificate; intermediate: secondary school certificate; high: general qualification for
university entrance
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Fig. 2 Cumulative incidence of HZ up to a given age by sex (left) and by birth-cohort (right)
Caputo et al. BMC Infectious Diseases           (2019) 19:99 Page 5 of 81973) compared to the older birth cohorts (1954 to 1963
and 1944 to 1953) (Fig. 2, right panel).Comparison of herpes zoster incidence rates based on
self-reports with estimates based on health insurance
data
Previous studies using health insurance data in Germany
(Table 1) reported all similar age-specific IR for HZ [2,
23, 24] (Fig. 3). In comparison to those estimates, the
age-specific IR estimates based on self-reports in the
pretest studies of the GNC were considerably lower.
However, the age-dependent increase of IR was similar
to that observed in health insurance data; the difference
between self-reported data and health insurance data
was approximately constant across age-groups. This also
applies to sex-specific differences with higher rates in fe-
males than males, especially above the age of 40 years
(Additional file 1). A sensitivity analysis was performed
by reclassifying participants who answered “Don’t know”Table 3 Effect of sex on HZ incidence stratified by age-group
Age-group (in years) Hazard Ratio (95%-CI) for
female vs male sexa
p-value
20 to 29 1.05 (0.80 to 1.38) 0.727
30 to 39 1.13 (0.74 to 1.72) 0.569
40 to 49 2.05 (1.36 to 3.13) < 0.001
50 to 59 1.62 (1.04 to 2.51) 0.031
60 to 69 1.96 (1.05 to 3.66) 0.035
aAdjusted for calendar timeinto the “No” group, which produced slightly smaller cu-
mulative incidences and IR (data not shown).
Proportion of herpes zoster cases developing
postherpetic neuralgia
Information about PHN was collected only in pretest 2
of the GNC. Of the 291 participants with a HZ episode,
10 reported to have suffered from PHN (3.4%; 95%-CI:
1.7 to 6.3%); this was less common than in studies using
health insurance data [24–26]. The proportion of PHN
in participants aged over 50 years was 5.9% (95%-CI: 1.9
to 13.9%), which is in line with one of the studies used
for comparison [2].
Discussion
We investigated the validity of self-reported diagnoses of
HZ in the pretest studies of the GNC by with by com-
parison with available estimates based on health insur-
ance data. While the age-specific pattern of the IR was
correctly reflected in the self-reported data, the esti-
mated IR in our study were lower compared to IR ob-
tained from health insurance data. Moreover, we found
evidence for a birth cohort effect with higher HZ inci-
dence in younger individuals.
Comparison with previous studies
A direct estimation of age- and sex-specific IR of HZ
based on the reported incidence in the past 12 months
was precluded by insufficient sample size. However,
given the anticipated large sample size of 200,000 indi-
viduals in the GNC [20], these estimates will still
Fig. 3 Comparison of incidence rates of HZ from GNC pretest
studies with German health insurance data. GNC: German National
Cohort; PY: Person-years; Depending on the study, 5- or 10-year age-
groups were used. The whiskers indicate 95%-CI
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current cumulative age-specific IR of HZ in Germany. In
comparison to IR based on health insurance data [2, 23,
24], the estimates from the GNC were considerably
lower across all age-groups. This can be either caused by
a selection of healthier participants in the GNC or by re-
call bias, particularly for episodes of HZ dating back de-
cades. It is also possible that individuals who recently
suffered from HZ did not participate in the pretest stud-
ies due to poor health conditions as the incidence of HZ
is much higher among individuals who suffered from se-
vere immune deficiency disorders (such as HIV or can-
cer). Selection mechanisms play a small role in health
insurance data especially if the study population is not
restricted to one very specific health insurance company.
The assumption of recall bias as an explanation for the
observed differences is supported by the observed birth
cohort effect. This is in line with previous findings show-
ing that the quality of self-reported diagnoses is affected
by the length of recall required (time since most recent
health exam) [4, 18] (in addition to factors like sex, age,
education, comorbidity, and natural course of the dis-
eases [8, 18, 27, 28]). However, the observed increase in
diagnosed IR of HZ could also be a true increase, which
would explain the birth cohort effects observed in our
study [14]. Several other studies, most of them based on
secondary data sources (e.g. outpatient, hospital, insur-
ance) with small potential for recall bias showed an in-
crease in IR of HZ over the past 50 years all over the
world [29]. The studies used for comparison in ourstudy were based on health insurance data from 2004 to
2009, while HZ episodes in the GNC were reported by
participants for the period between 1944 and 2012. One
possible explanation for this increase is the so-called
boosting-hypothesis; namely the contact with varicella
protects those infected with VZV from reactivation of
the virus as HZ. Decreasing fertility, aging population,
and the introduction of vaccination against varicella in
Germany in 2004 all contribute to reducing the exposure
to varicella, which in turn leads to an increase in the
number of HZ cases in unvaccinated individuals [29]. A
further reason for the observed difference could be re-
lated to an overestimation of the true IR of HZ in
studies using health insurance data. It has been reported
previously (even for HZ [23]) that health insurance data
tend to overestimate the true IR in some diseases
because they are based on claims data.
Sex- and age-specific pattern of herpes zoster incidence
rates
While age-specific IR of HZ were lower than in the studies
used for comparison, the characteristic age-dependent in-
crease of IR of HZ with a substantial rise above 40 years of
age was reproduced in the self-reported data; the effect was
more pronounced among female than male participants.
We identified an effect of sex on HZ incidence above the
age of 40 years with female participants having about two
times higher hazard of HZ compared to male participants.
These sex-specific differences have also been shown in pre-
vious studies from Germany. The underlying physiologic
reasons, however, have not yet been identified [23, 24]. An
advanced age is known to be an important risk factor for
HZ as a consequence of immune senescence-induced
weakening of the immune response, which promotes a re-
activation of latent-persistent VZV [1, 30].
Estimation of postherpetic neuralgia proportion
Since information on PHN was collected only in pre-
test 2 and only a small fraction of persons with HZ
developed PHN, precision of PHN estimation was
low, preventing a stratification by age despite the
known strong increase of PHN with age. The litera-
ture varies considerably regarding estimates of PHN
proportions (4.5 to 20.6%) due to differences in study
design, population, and definition of pain duration of
PHN [2, 24, 26, 31, 32].
Strength and limitations
The main strength of our study is the relatively large
sample size, including persons contributing self-reported
data from various regions of Germany. Moreover, the
stratified random sampling of participants from local
registration offices in the study regions was
population-based. Given the very broad scope of the
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selves into the study based on their interest in HZ. How-
ever, several limitations of our study need to be
mentioned. Medical records or physician examinations
of diagnosed HZ cases were not available for study par-
ticipants of the pretest studies. Accordingly, we could
not attempt a direct validation of disease data against
medical records, which is the gold standard for assessing
the validity of self-reported data on an individual level.
Instead, we compared aggregate measures based on
self-reported and health insurance data. A prerequisite
for such a comparison is the representativeness of both
study populations with respect to the source population;
given the relatively low response proportion in our
study, this might have not been the case. The use of
published data for indirect comparisons represents a
simple approach, which is however limited to informa-
tion available in the sources used as reference. For ex-
ample, definitions of PHN differed in previous
publications; this might explain the heterogeneity of data
on this outcome in the literature. As information on the
first HZ episode could only be reported in the pretest
studies, subsequent HZ episodes could not be consid-
ered in the analysis. However, for estimating the IR we
censored person-time after the first reported HZ episode
under the assumption, that the risk of HZ is not affected
by past HZ episodes [33].Conclusion
We investigated the validity of self-reported diagnoses of
HZ from a population-based study in Germany by com-
paring them with estimates from health insurance data.
We found consistently lower IRs of HZ based on
self-reported data compared to health insurance data as
well as a birth cohort effect. Age- and sex-specific differ-
ences in IRs followed the patterns of estimates based on
health insurance data in Germany.Additional file
Additional file 1: Herpes zoster incidence in Germany: an indirect
validation study for self-reported disease data from the pretest studies of
the German National Cohort. Comparison of age-specific incidence rates
(per 1000 PY) of herpes zoster from pretest studies of the German Na-
tional Cohort with studies based on health insurance data in Germany by
sex. A: Comparison of incidence rates of herpes zoster (per 1000 PY) in fe-
male participants. B: Comparison of incidence rates of herpes zoster (per
1000 PY) in male participants. GNC: German National Cohort. PY: Person-
years. (TIF 130 kb)Abbreviations
CI: Confidence interval; GNC: German National Cohort; HZ: Herpes zoster;
IQR: Interquartile range; IR: Incidence rate; PHN: Postherpetic neuralgia;
PY: Person-years; VS: Versus; VZV: Varicella zoster virus; Y: YearAcknowledgements
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